Clinical Trials Logo
  1. Home
  2. Steroid-Induced Glaucoma
  3. NCT04593745

Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids — ALL  

ALL, Childhood Clinical Trial

Official title:
Intraocular Pressure in Children With ALL Treated With High Dose Steroids

Clinical Trial Summary

Childhood ALL patients are treated with high dose steroids. The study will follow the intraocular pressure of children treated in according to an AIEOP-BFM protocol, during the induction phase that will be compared to the pressure before treatment. Potential risk factors for developing elevated intraocular pressure will be estimated.

Clinical Trial Description

Children with ALL in Israel are treating according to the BFM ALL Protocol which contains high dose steroid therapy. One of the known side effects of high dose steroids is Intraocular hypertension, glaucoma, and even irreversible optic nerve injury. Early diagnosis of elevated intraocular pressure (IOP) and early therapeutic interventions might help to prevent future ocular damage. The purpose of this study is to determine the risk of developing evaluate Intraocular pressure during high dose steroid therapy. If elevated IOP will be common enough, we will try to corelate the risk of elevated IOP with potential risk factors, such as initial IOP, WBC at diagnosis, etc. Intraocular pressure will be measured by ophthalmologists using iCare devise: TONOPEN during general anesthesia at the day of diagnosis of ALL before steroid therapy initiation, and then after 15 and 33 days. Children with elevated IOP will continue ophthalmologists' follow up and treatment as necessary. All parents or patients' guardians will sign informed consent for participating in the study. The study group contains all newly diagnosed children with ALL in Schneider Children Medical Center. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04593745
Study type Interventional
Source Rabin Medical Center
Contact Shlomit Barzilai Birenboim, MD
Phone 03-9253461
Email Bshlomit@clalit.org.il
Status Recruiting
Phase N/A
Start date July 9, 2018
Completion date July 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05487651 - Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies Phase 1
Not yet recruiting NCT06050850 - A Healthy Weight Intervention for Family Stress During the Early Phases of ALL Treatment: NOURISH-ALL
Recruiting NCT03571321 - Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Phase 1
Not yet recruiting NCT06326463 - CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Phase 1
Terminated NCT01100658 - Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors N/A
Recruiting NCT05763290 - Childhood Cancer Survivors' Affective Response to Exercise
Not yet recruiting NCT06389357 - Return to School Adaptation Programme for Children With Cancer N/A
Recruiting NCT02879643 - Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL Phase 1
Active, not recruiting NCT03817320 - PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Phase 1/Phase 2
Terminated NCT04785547 - ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT Phase 2
Recruiting NCT05512169 - Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
Completed NCT03627208 - Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
Not yet recruiting NCT03889951 - Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy